<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751399</url>
  </required_header>
  <id_info>
    <org_study_id>14205</org_study_id>
    <secondary_id>I2R-MC-BIDA</secondary_id>
    <nct_id>NCT01751399</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of LY2605541 in Participants With Liver Impairment</brief_title>
  <official_title>A Single Dose Pharmacokinetic Study of LY2605541 in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to help answer the following research questions:

        -  To evaluate how much of the study drug (LY2605541) is in the blood of participants with
           varying degrees of liver impairment compared to those with normal liver function

        -  To assess the safety of LY2605541 and any side effects that might be associated with it
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted in 4 groups, based on the Child-Pugh classification of hepatic
      impairment as follows:

      Group 1: Participants with normal hepatic function (Control); Group 2: Participants with mild
      hepatic impairment (Child-Pugh class A); Group 3: Participants with moderate hepatic
      impairment (Child-Pugh class B); and Group 4: Participants with severe hepatic impairment
      (Child-Pugh class C).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-âˆž]) of LY2605541</measure>
    <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541</measure>
    <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Hepatic Insufficiency</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY2605541-Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal hepatic function will receive a single subcutaneous (SC) dose of 0.075 milligrams per kilogram (mg/kg) LY2605541</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541-Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541-Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541-Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2605541</intervention_name>
    <arm_group_label>LY2605541-Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>LY2605541-Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>LY2605541-Normal Hepatic Function</arm_group_label>
    <arm_group_label>LY2605541-Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Participants (including those with type 2 diabetes mellitus [T2DM] who are controlled
        by diet)

          -  Male participants agree to use a reliable method of birth control during the study

          -  Female participants of child-bearing potential (not surgically sterilized between
             menarche and menopause) must have a negative pregnancy test at the time of enrollment
             and must be using a reliable method of birth control

          -  Women of non-child-bearing potential due to surgical sterilization (at least 6 weeks
             after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks
             after tubal ligation) confirmed by medical history, or menopause.

          -  Menopausal women include women with either spontaneous amenorrhea for at least 12
             months or spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone
             (FSH) level greater than 40 milli international units per milliliter (mIU/mL)

          -  Have a body mass index (BMI) of 18.5 to 40 kilogram per square meter (kg/m^2)

          -  Have normal sitting blood pressure and heart rate compatible with their disease state

          -  Have venous access sufficient to allow blood sampling

          -  Have given written informed consent approved by Lilly and the Ethical Review Board
             (ERB) governing the site

        Participants with Normal Hepatic Function

          -  Overtly healthy males or females with normal hepatic function

          -  Have clinical laboratory test results within normal reference range for the
             investigator site, or results with minor deviations not considered to be clinically
             significant by the investigator

        Participants with Hepatic Impairment

          -  Have stable liver impairment with no sign of recent deterioration (alcoholic,
             posthepatitis, biliary cirrhosis, or cryptogenic) classified as Child-Pugh class A, B,
             or C who are considered by the investigator as acceptable for participation in the
             study

        Exclusion Criteria:

        All Participants (including those with T2DM)

          -  Are currently enrolled in, have completed or discontinued within the last 30 days from
             a clinical trial involving an investigational product, or are concurrently enrolled in
             any other type of medical research judged not to be scientifically or medically
             compatible with this study

          -  Have an acute infection with fever or infectious disease or febrile illness within 3
             days prior to administration of the study medication

          -  Have known allergies or significant hypersensitivity to LY2605541, its excipients, or
             related compounds, or history of relevant allergic reactions of any origin

          -  Have previously completed or withdrawn from this study or any other study
             investigating LY2605541 and have previously received the investigational product

          -  Have Type 1 Diabetes Mellitus (T1DM) or have T2DM and are receiving anti-diabetic
             medication

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
             investigator, increases the risks associated with participating in the study

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV
             antibodies

          -  Have donated blood of more than 500 milliliters (mL) within the last month

          -  Have had a liver transplant or have taken immunosuppressants following any organ
             transplant

          -  Have shown signs of variceal bleeding during the last 2 weeks prior to screening

          -  Show evidence of irritable bowel syndrome, chronic diarrhea, other symptomatic
             digestive problems or a known history of repeated chronic stool positive for occult
             blood, or be considered by the investigator to be at greater risk of acute or chronic
             pancreatitis

          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
             units per week (females), or are unwilling to stop alcohol consumption for the
             duration of the study (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of
             wine; 1.5 oz or 45 mL of distilled spirits)

          -  Are on total parenteral nutrition

          -  Take anticoagulants for therapeutic use, other than low dose acetylsalicyclic acid

          -  Are excessive consumers of xanthines

        Participants with Normal Hepatic Function

          -  Have any medically significant history of neurologic disease, cancer, or cardiac,
             respiratory, metabolic, hepatic, renal, gastrointestinal (except appendectomy and
             cholecystectomy), dermatological, venereal, hematological disorder or disease

          -  Have creatinine clearance (CrCl) less than 80 milliliters per minute (mL/min)

          -  Show evidence of significant active neuropsychiatric disease in the opinion of the
             investigator

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

        Participants with Hepatic Impairment

          -  Show evidence of any significant active disease other than that responsible for or
             associated with mild, moderate, or severe hepatic impairment

          -  Show evidence of hepatorenal syndrome as shown by CrCl &lt;50 mL/min calculated using the
             Cockcroft-Gault equation

          -  Have shown signs of spontaneous bacterial peritonitis within 6 months prior to
             enrollment into the study

          -  Have severe hyponatremia (sodium &lt;120 millimoles per liter [mmol/L])

          -  Show signs of hepatocellular carcinoma

          -  Have a portal shunt

          -  Show, in the opinion of the investigator, evidence of significant active
             neuropsychiatric disease other than grade 1 hepatic encephalopathy

          -  Have hemoglobin concentrations &lt;9.0 grams per deciliter (g/dL)

          -  Have a platelet count of &lt;30 x 10^9 cells per liter (cells/L), unless, after
             consultation with the sponsor, they are considered as acceptable for participation in
             the study

          -  Have total serum bilirubin concentrations &gt;15 milligrams per deciliter (mg/dL) (&gt;257
             micromoles per liter [Î¼mol/L])

          -  Take medications known to interfere with hepatic metabolism (for example barbiturates
             or phenothiayines) or known to alter other major organ systems

          -  Show signs of acute cholestasis or acute cholecystitis

          -  Have severe ascites
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munich</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <results_first_submitted>March 17, 2018</results_first_submitted>
  <results_first_submitted_qc>March 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2018</results_first_posted>
  <last_update_submitted>March 17, 2018</last_update_submitted>
  <last_update_submitted_qc>March 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LY2605541-Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single subcutaneous (SC) dose of 0.075 milligrams per kilogram (mg/kg) LY2605541</description>
        </group>
        <group group_id="P2">
          <title>LY2605541-Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="P3">
          <title>LY2605541-Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="P4">
          <title>LY2605541-Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants.</population>
      <group_list>
        <group group_id="B1">
          <title>LY2605541-Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="B2">
          <title>LY2605541-Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="B3">
          <title>LY2605541-Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="B4">
          <title>LY2605541-Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="6.4"/>
                    <measurement group_id="B2" value="56.0" spread="5.9"/>
                    <measurement group_id="B3" value="52.4" spread="9.9"/>
                    <measurement group_id="B4" value="57.6" spread="3.3"/>
                    <measurement group_id="B5" value="54.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-âˆž]) of LY2605541</title>
        <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
        <population>All participants who received 1 dose of LY2605541 and had evaluable AUC(0-âˆž) data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2605541-Normal Hepatic Function</title>
            <description>Participants with normal hepatic function received a single SC dose of 0.075 mg/kg LY2605541</description>
          </group>
          <group group_id="O2">
            <title>LY2605541-Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
          </group>
          <group group_id="O3">
            <title>LY2605541-Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
          </group>
          <group group_id="O4">
            <title>LY2605541-Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-âˆž]) of LY2605541</title>
          <population>All participants who received 1 dose of LY2605541 and had evaluable AUC(0-âˆž) data.</population>
          <units>picomole*hours/liter (pmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85200" spread="19"/>
                    <measurement group_id="O2" value="67200" spread="31"/>
                    <measurement group_id="O3" value="64300" spread="65"/>
                    <measurement group_id="O4" value="66600" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541</title>
        <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
        <population>All participants who received 1 dose of LY2605541 and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2605541-Normal Hepatic Function</title>
            <description>Participants with normal hepatic function received a single SC dose of 0.075 mg/kg LY2605541</description>
          </group>
          <group group_id="O2">
            <title>LY2605541-Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
          </group>
          <group group_id="O3">
            <title>LY2605541-Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
          </group>
          <group group_id="O4">
            <title>LY2605541-Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541</title>
          <population>All participants who received 1 dose of LY2605541 and had evaluable Cmax data.</population>
          <units>pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1300" spread="38"/>
                    <measurement group_id="O2" value="946" spread="73"/>
                    <measurement group_id="O3" value="1180" spread="163"/>
                    <measurement group_id="O4" value="1090" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY2605541-Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="E2">
          <title>LY2605541-Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="E3">
          <title>LY2605541-Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
        <group group_id="E4">
          <title>LY2605541-Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single SC dose of 0.075 mg/kg LY2605541</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

